Search

Your search keyword '"Dongiovanni, Paola"' showing total 702 results

Search Constraints

Start Over You searched for: Author "Dongiovanni, Paola" Remove constraint Author: "Dongiovanni, Paola"
702 results on '"Dongiovanni, Paola"'

Search Results

1. Simultaneous Detection of pH, Antioxidant Capacity and Conductivity Through a Low-Cost Wireless Sensing Platform

2. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

5. Author Correction: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

6. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors

9. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

10. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease

12. Artificial intelligence as a ploy to delve into the intricate relationship between genetics and mitochondria in MASLD patients

13. TOP-301 Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease

19. Hepatic and adipose tissue transcriptome analysis highlights a commonly deregulated autophagic pathway in severe MASLD

20. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

21. PSD3 downregulation confers protection against fatty liver disease

22. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models

23. Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19]

24. Cholesterol-Associated Locus EHBP1 Protects Against MASH Fibrosis

31. SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease

32. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors

33. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

34. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells

35. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

36. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

38. Metabolic associated fatty liver disease: different impact of the three defining criteria on the hepatic and cardiovascular complications

39. The PNPLA3 I148M variant aggravates inflammation through dysfunctional LXR and PPAR gamma signalling in macrophages

40. The PNPLA3 I148M variant initiates metabolic reprogramming in macrophages

41. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease

42. Combined hepatic and adipose tissue transcriptomics highlights circulating NASH biomarkers

46. A functional interaction between hepatic estrogen receptor-α and PNPLA3 p.I148M inherited variant drives fatty liver disease susceptibility in women

49. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Catalog

Books, media, physical & digital resources